These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32467965)

  • 41. Adverse outcome pathways: opportunities, limitations and open questions.
    Leist M; Ghallab A; Graepel R; Marchan R; Hassan R; Bennekou SH; Limonciel A; Vinken M; Schildknecht S; Waldmann T; Danen E; van Ravenzwaay B; Kamp H; Gardner I; Godoy P; Bois FY; Braeuning A; Reif R; Oesch F; Drasdo D; Höhme S; Schwarz M; Hartung T; Braunbeck T; Beltman J; Vrieling H; Sanz F; Forsby A; Gadaleta D; Fisher C; Kelm J; Fluri D; Ecker G; Zdrazil B; Terron A; Jennings P; van der Burg B; Dooley S; Meijer AH; Willighagen E; Martens M; Evelo C; Mombelli E; Taboureau O; Mantovani A; Hardy B; Koch B; Escher S; van Thriel C; Cadenas C; Kroese D; van de Water B; Hengstler JG
    Arch Toxicol; 2017 Nov; 91(11):3477-3505. PubMed ID: 29051992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia.
    ; Ockleford C; Adriaanse P; Berny P; Brock T; Duquesne S; Grilli S; Hernandez-Jerez AF; Bennekou SH; Klein M; Kuhl T; Laskowski R; Machera K; Pelkonen O; Pieper S; Smith R; Stemmer M; Sundh I; Teodorovic I; Tiktak A; Topping CJ; Wolterink G; Angeli K; Fritsche E; Hernandez-Jerez AF; Leist M; Mantovani A; Menendez P; Pelkonen O; Price A; Viviani B; Chiusolo A; Ruffo F; Terron A; Bennekou SH
    EFSA J; 2017 Mar; 15(3):e04691. PubMed ID: 32625422
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.
    Pelkonen O; Terron A; Hernandez AF; Menendez P; Bennekou SH;
    Arch Toxicol; 2017 Aug; 91(8):2763-2780. PubMed ID: 28536863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiation adverse outcome pathways (AOPs) are on the horizon: advancing radiation protection through an international Horizon-Style exercise.
    Burtt JJ; Leblanc J; Randhawa K; Ivanova A; Rudd MA; Wilkins R; Azzam EI; Hecker M; Horemans N; Vandenhove H; Adam-Guillermin C; Armant O; Klokov D; Audouze K; Kaiser JC; Moertl S; Lumniczky K; Tanaka IB; Yamada Y; Hamada N; Al-Nabulsi I; Preston RJ; Bouffler S; Applegate K; Cool D; Beaton D; Tollefsen KE; Garnier-Laplace J; Laurier D; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1763-1776. PubMed ID: 36067511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an adverse outcome pathway for radiation-induced microcephaly via expert consultation and machine learning.
    Jaylet T; Quintens R; Benotmane MA; Luukkonen J; Tanaka IB; Ibanez C; Durand C; Sachana M; Azimzadeh O; Adam-Guillermin C; Tollefsen KE; Laurent O; Audouze K; Armant O
    Int J Radiat Biol; 2022; 98(12):1752-1762. PubMed ID: 35947014
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linking Mitochondrial Dysfunction to Organismal and Population Health in the Context of Environmental Pollutants: Progress and Considerations for Mitochondrial Adverse Outcome Pathways.
    Dreier DA; Mello DF; Meyer JN; Martyniuk CJ
    Environ Toxicol Chem; 2019 Aug; 38(8):1625-1634. PubMed ID: 31034624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PTID: an integrated web resource and computational tool for agrochemical discovery.
    Gong J; Liu X; Cao X; Diao Y; Gao D; Li H; Qian X
    Bioinformatics; 2013 Jan; 29(2):292-4. PubMed ID: 23162083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Putative adverse outcome pathways for female reproductive disorders to improve testing and regulation of chemicals.
    Johansson HKL; Damdimopoulou P; van Duursen MBM; Boberg J; Franssen D; de Cock M; Jääger K; Wagner M; Velthut-Meikas A; Xie Y; Connolly L; Lelandais P; Mazaud-Guittot S; Salumets A; Draskau MK; Filis P; Fowler PA; Christiansen S; Parent AS; Svingen T
    Arch Toxicol; 2020 Oct; 94(10):3359-3379. PubMed ID: 32638039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of the adverse outcome pathway (AOP) approach to inform mode of action (MOA): A case study with inorganic arsenic.
    Clewell HJ; Yager JW; Greene TB; Gentry PR
    J Toxicol Environ Health A; 2018; 81(18):893-912. PubMed ID: 30230972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of adverse outcome pathway networks to integrate mechanistic data informing the choice of a point of departure for hydrogen sulfide exposure limits.
    Goyak KO; Lewis RJ
    Crit Rev Toxicol; 2021 Mar; 51(3):193-208. PubMed ID: 33905294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AOP report: Development of an adverse outcome pathway for oxidative DNA damage leading to mutations and chromosomal aberrations.
    Cho E; Allemang A; Audebert M; Chauhan V; Dertinger S; Hendriks G; Luijten M; Marchetti F; Minocherhomji S; Pfuhler S; Roberts DJ; Trenz K; Yauk CL
    Environ Mol Mutagen; 2022 Mar; 63(3):118-134. PubMed ID: 35315142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of the adverse outcome pathway framework to genotoxic modes of action.
    Sasaki JC; Allemang A; Bryce SM; Custer L; Dearfield KL; Dietz Y; Elhajouji A; Escobar PA; Fornace AJ; Froetschl R; Galloway S; Hemmann U; Hendriks G; Li HH; Luijten M; Ouedraogo G; Peel L; Pfuhler S; Roberts DJ; Thybaud V; van Benthem J; Yauk CL; Schuler M
    Environ Mol Mutagen; 2020 Jan; 61(1):114-134. PubMed ID: 31603995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study.
    Jin Y; Feng M; Ma W; Wei Y; Qi G; Luo J; Xu L; Li X; Li C; Wang Y; Li D; Chen J; Zhao Y; Hou Y; Zhao Q; Jiang L; Xie M; Zheng Y; Yu D
    Environ Pollut; 2021 Jan; 268(Pt B):115733. PubMed ID: 33011576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole.
    Luckert C; Braeuning A; de Sousa G; Durinck S; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg AACM; Rahmani R; Rajkovic A; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla S; Wollscheid B; Zucchini-Pascal N; Lampen A
    Chem Res Toxicol; 2018 Aug; 31(8):784-798. PubMed ID: 29995386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.
    Rolo D; Tavares A; Vital N; Silva MJ; Louro H
    Adv Exp Med Biol; 2022; 1357():415-439. PubMed ID: 35583654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity.
    Bal-Price A; Lein PJ; Keil KP; Sethi S; Shafer T; Barenys M; Fritsche E; Sachana M; Meek MEB
    Neurotoxicology; 2017 Mar; 59():240-255. PubMed ID: 27212452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.